Cortical beta-amyloid burden, neuropsychiatric symptoms, and cognitive status: the Mayo Clinic Study of Aging
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F19%3A00071071" target="_blank" >RIV/00159816:_____/19:00071071 - isvavai.cz</a>
Výsledek na webu
<a href="https://www.nature.com/articles/s41398-019-0456-z.pdf" target="_blank" >https://www.nature.com/articles/s41398-019-0456-z.pdf</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1038/s41398-019-0456-x" target="_blank" >10.1038/s41398-019-0456-x</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Cortical beta-amyloid burden, neuropsychiatric symptoms, and cognitive status: the Mayo Clinic Study of Aging
Popis výsledku v původním jazyce
Neuropsychiatric symptoms (NPS) are a risk factor for cognitive impairment and are associated with cortical beta-amyloid (A beta) deposition. We conducted a cross-sectional study derived from the ongoing population-based Mayo Clinic Study of Aging to examine the frequency of NPS among cognitively unimpaired (CU) and mild cognitive impairment (MCI) participants who either have normal (A-) or abnormal (A+) A beta deposition. We also investigated whether combined presence of MCI and amyloid positivity (MCl/A+) is associated with greater odds of having NPS as compared to CU/A- (defined as reference group). Participants were 1627 CU and MCI individuals aged >= 50 years (54% males; median age 73 years). All participants underwent NPS assessment (Neuropsychiatric Inventory Questionnaire (NPI-Q); Beck Depression Inventory II (BDI-II); Beck Anxiety Inventory (BAI)) and C-11-PiB-PET. Participants with an SUVR > 1.42 were classified as A+. We conducted multivariable logistic regression analyses adjusted for age, sex, education, and APOE epsilon 4 genotype status. The sample included 997 CU/A-, 446 CU/A+, 78 MCl/A-, and 106 MCI/A+ persons. For most NPS, the highest frequency of NPS was found in MCI/A+ and the lowest in CU/A-. The odds ratios of having NPS, depression (BDI >= 13), or anxiety (BAI >= 8, >= 10) were consistently highest for MCl/A+ participants. In conclusion, MCI with A beta burden of the brain is associated with an increased risk of having NPS as compared to MCI without A beta burden. This implies that the underlying Alzheimer's disease biology (i.e., cerebral A beta amyloidosis) may drive both cognitive and psychiatric symptoms.
Název v anglickém jazyce
Cortical beta-amyloid burden, neuropsychiatric symptoms, and cognitive status: the Mayo Clinic Study of Aging
Popis výsledku anglicky
Neuropsychiatric symptoms (NPS) are a risk factor for cognitive impairment and are associated with cortical beta-amyloid (A beta) deposition. We conducted a cross-sectional study derived from the ongoing population-based Mayo Clinic Study of Aging to examine the frequency of NPS among cognitively unimpaired (CU) and mild cognitive impairment (MCI) participants who either have normal (A-) or abnormal (A+) A beta deposition. We also investigated whether combined presence of MCI and amyloid positivity (MCl/A+) is associated with greater odds of having NPS as compared to CU/A- (defined as reference group). Participants were 1627 CU and MCI individuals aged >= 50 years (54% males; median age 73 years). All participants underwent NPS assessment (Neuropsychiatric Inventory Questionnaire (NPI-Q); Beck Depression Inventory II (BDI-II); Beck Anxiety Inventory (BAI)) and C-11-PiB-PET. Participants with an SUVR > 1.42 were classified as A+. We conducted multivariable logistic regression analyses adjusted for age, sex, education, and APOE epsilon 4 genotype status. The sample included 997 CU/A-, 446 CU/A+, 78 MCl/A-, and 106 MCI/A+ persons. For most NPS, the highest frequency of NPS was found in MCI/A+ and the lowest in CU/A-. The odds ratios of having NPS, depression (BDI >= 13), or anxiety (BAI >= 8, >= 10) were consistently highest for MCl/A+ participants. In conclusion, MCI with A beta burden of the brain is associated with an increased risk of having NPS as compared to MCI without A beta burden. This implies that the underlying Alzheimer's disease biology (i.e., cerebral A beta amyloidosis) may drive both cognitive and psychiatric symptoms.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30215 - Psychiatry
Návaznosti výsledku
Projekt
<a href="/cs/project/LQ1605" target="_blank" >LQ1605: Translační medicína</a><br>
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Ostatní
Rok uplatnění
2019
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Translational Psychiatry
ISSN
2158-3188
e-ISSN
—
Svazek periodika
9
Číslo periodika v rámci svazku
March
Stát vydavatele periodika
US - Spojené státy americké
Počet stran výsledku
8
Strana od-do
—
Kód UT WoS článku
000466709300003
EID výsledku v databázi Scopus
—